Free Submission Public Relations &
Deutsch English

OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017

Global AML therapy market: Majority of sales from the US

Print article Print article
2014-01-30 07:05:03 - OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017 - a new market research report on

Driven by a boost in new therapies entering the market, as well as an increasing number of Acute Myeloid Leukemia (AML) cases among elderly patients, the AML market will grow significantly between 2012 and 2017. However, lackluster results from clinical studies and cost-consciousness may continue to plague drug development.

Revenue for the AML market across the US, France, Germany, Italy, Spain, and the UK will increase from $151 million in 2012 to $430.7 million in 2017, representing a Compound Annual Growth Rate (CAGR) of 23.3%.

In 2012, the majority of the AML therapies sales were generated in the US, which enjoyed a market share of $108.8 million, while sales in the 5EU countries were estimated to be approximately $42 million. By 2017,



the AML market in the US and the 5EU countries is expected to reach $324.4 million and $106.3 million in sales, respectively.

The increase in the AML market size, particularly in the US, will be primarily due to the launch of new therapies for patients with high unmet needs, states the report. Such therapies include Sunesis´ vosaroxin for relapsed and refractory AML, Novartis´ midostaurin for patients with FLT3 mutations and Cyclacel´s sapacitabine for newly-diagnosed elderly patients.

Although AML is a rare disease, the high levels of unmet needs create ample opportunities for players with effective therapies. However, drug development in this area has been very challenging, as products have shown promise in the early phase, but failed in larger, randomized studies. Further barriers to the discovery of effective therapies have also included a general lack of understanding of the biology that drives the disease.

Other limitations for the development of new therapies include the pressure for cost-consciousness, which will restrict the reimbursement of new market entrants, and the lack of breakthrough efficacy of pipeline drugs, which has failed to impress clinicians.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Mike King
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact